How were Second Sight Medical Products' earnings last quarter?

Second Sight Medical Products, Inc. (NASDAQ:EYES) released its quarterly earnings data on Monday, June, 29th. The medical device company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.23) by $0.48.

When did Second Sight Medical Products' stock split?

Second Sight Medical Products shares reverse split on Friday, August 19th 2022. The 1-3 reverse split was announced on Friday, August 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

What is Will McGuire's approval rating as Second Sight Medical Products' CEO?

5 employees have rated Second Sight Medical Products Chief Executive Officer Will McGuire on Glassdoor.com . Will McGuire has an approval rating of 57% among the company's employees. This puts Will McGuire in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Second Sight Medical Products own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE) , Adaptimmune Therapeutics (ADAP) , Cara Therapeutics (CARA) , VBI Vaccines (VBIV) , Shopify (SHOP) , Corbus Pharmaceuticals (CRBP) , Sorrento Therapeutics (SRNE) , Ekso Bionics (EKSO) and OPKO Health (OPK) .

When did Second Sight Medical Products IPO?

Second Sight Medical Products (EYES) raised $32 million in an initial public offering on Wednesday, November 19th 2014. The company issued 3,500,000 shares at $9.00 per share. MDB Capital Group, LLC served as the underwriter for the IPO.

NASDAQ:EYES

Second Sight Medical Products (EYES) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Free EYES Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $4.11
▼
$13.05
52-Week Range: N/A

Volume: 36,800 shs
Average Volume: 132,982 shs
Market Capitalization: $54.38 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Second Sight Medical Products alerts:

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

About Second Sight Medical Products Stock (NASDAQ:EYES)

Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

EYES Stock News Headlines

April 12, 2024 | msn.com

I’m Trying the Sarah Hyland-Approved Under-Eye Patches That Reviewers Say Work ‘Miracles’

March 16, 2024 | msn.com

Scary but Normal Baby Problems and How to Solve Them

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

March 16, 2024 | yahoo.com

An Optometrist Shared The One Eye Product We Should All Stop Using

March 15, 2024 | msn.com

Another dangerous amoeba has been linked to neti pots, nasal rinsing: What to know

March 14, 2024 | msn.com

Viking Soul Food Will Close Its Stalwart Belmont Street Food Cart

March 14, 2024 | yahoo.com

Experts recommend eye safety during eclipse

March 13, 2024 | msn.com

Another dangerous amoeba has been linked to neti pots and nasal rinsing. Here’s what to know

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

February 18, 2024 | msn.com

Dandelions and shrubs to replace rubber, new grains and more: Are alternative crops realistic?

February 2, 2024 | msn.com

FDA warns of ‘copycat’ eye drops that can cause eye infection

February 1, 2024 | msn.com

How to Stop Skin Picking for Even Just a Second

January 4, 2024 | msn.com

All eyes are on glaucoma, the ‘silent thief of sight’ — and the truth behind 7 myths

December 29, 2023 | msn.com

SightCare: Eye Health Revolution or False Hope? Unbiased Look at Sight Care Supplement Reviews!

November 16, 2023 | sfgate.com

FDA's latest warnings about eye drop contamination put consumers on edge − a team of infectious disease experts explain the risks

September 25, 2023 | benzinga.com

Orbis International Teams Up with the Alcon Foundation and OMEGA to Improve Eye Care in Zambia

September 22, 2023 | msn.com

A new season of infections is here, but the shortage of a common kids’ antibiotic never ended

September 14, 2023 | msn.com

Piper Sandler Downgrades Sight Sciences (SGHT)

August 15, 2023 | uk.finance.yahoo.com

Posterior Segment Eye Disorders Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)

April 4, 2023 | msn.com

I’d lost my sight, but thanks to a pioneering new ‘bionic eye’ I can do some gardening again

March 29, 2023 | dailymail.co.uk

Eye patients are slowly losing their sight because they are stuck in the NHS backlog

March 24, 2023 | msn.com

60 Photos From History You Probably Haven't Seen Yet

February 23, 2023 | marketwatch.com

Bionic Eye Market Future Trends Demand 2023, and Forecast to 2028

January 11, 2023 | thestreet.com

Second Sight Medical Products (EYES) Stock Rises Today on Positive Clinical Results

December 14, 2022 | marketwatch.com

Bionic Eye Market Size, Share and Forecast till 2028 with Top Countries Data

December 5, 2022 | msn.com

Dr. Charissa Lee: 'Prioritize your eyes' for optimum well-being at every age

November 13, 2022 | seekingalpha.com

Sight Sciences, Inc. (SGHT) Q3 2022 Earnings Call Transcript

See More Headlines

Receive EYES Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Second Sight Medical Products and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 6/29/2020
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Electromedical Equipment
Sub-Industry: N/A
Current Symbol: NASDAQ:EYES
CUSIP: N/A
CIK: 1266806
Web: www.secondsight.com
Phone: (818) 833-5000
Fax: 818-833-5067
Employees: 15
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-8,920,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -13.58%
Return on Assets: -13.02%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 22.15
Quick Ratio: 22.15

Sales & Book Value

Annual Sales: $3.38 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.80 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 13,135,000
Free Float: 6,935,000
Market Cap: $54.38 million
Optionable: Optionable
Beta: 2.55

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Mr. Scott Dunbar (Age 64)
Acting Chief Exec. Officer
Comp: $301.39k
Mr. Edward Jonathon Sedo (Age 66)
Acting Chief Accounting Officer, Principal Financial Officer & Controller
Comp: $199.18k
Mr. Edward David Randolph (Age 64)
Chief Operating Officer
Comp: $366.44k
Gunnar Bjorg
Founder
Ms. Lisa M. Wilson (Age 57)
Founder & Pres of In-Site Communications and Investor Relations for Second Sight

Key Competitors

View All Competitors

EYES Stock Analysis - Frequently Asked Questions

How were Second Sight Medical Products' earnings last quarter?: Second Sight Medical Products, Inc. (NASDAQ:EYES) released its quarterly earnings data on Monday, June, 29th. The medical device company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.23) by $0.48.
When did Second Sight Medical Products' stock split?: Second Sight Medical Products shares reverse split on Friday, August 19th 2022. The 1-3 reverse split was announced on Friday, August 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.
What is Will McGuire's approval rating as Second Sight Medical Products' CEO?: 5 employees have rated Second Sight Medical Products Chief Executive Officer Will McGuire on Glassdoor.com. Will McGuire has an approval rating of 57% among the company's employees. This puts Will McGuire in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Second Sight Medical Products own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE), Adaptimmune Therapeutics (ADAP), Cara Therapeutics (CARA), VBI Vaccines (VBIV), Shopify (SHOP), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), Ekso Bionics (EKSO) and OPKO Health (OPK).
When did Second Sight Medical Products IPO?: Second Sight Medical Products (EYES) raised $32 million in an initial public offering on Wednesday, November 19th 2014. The company issued 3,500,000 shares at $9.00 per share. MDB Capital Group, LLC served as the underwriter for the IPO.

This page (NASDAQ:EYES) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Second Sight Medical Products (EYES) Stock Price, News & Analysis

About Second Sight Medical Products Stock (NASDAQ:EYES)

EYES Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

EYES Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info